Abstract:A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. Cancer Drug-Resistance Overview The development of targeted therapies has brought much promise to overcoming cancer as a compendium of different genomic diseases [1]. However, the success of such personalized therapies was quickly met with varying degrees of drug resistance. Therefore, it is instructive to study the mechanisms of drug resistance in parallel with the development of the drug itself, in anticipation that understanding the eventual drug resistance would result in strategies to overcome such outcomes. Both intrinsic and acquired drug resistance need to be addressed. ‘Intrinsic resistance’ indicates that resistance-mediating factors are present in tumor tissues before receiving treatment, while ‘acquired resistance’ refers to resistance mechanisms that develop after the drug treatment of tumors that are initially responsive. The distinction between these two broad categories of resistance is sometimes blurred by the heterogeneity of tumor tissues, because acquired resistance may be caused by the presence of a rare resistant subpopulation of cells in the original tumor [2]. The recent advances in genomic methods have greatly accelerated our understanding of cancer drug resistance. In this review, we briefly summarize the major biochemical and genetic mechanisms causing cancer drug resistance, and then focus primarily on the genomic approaches commonly used to reveal the genetic changes underlying those major mechanisms.

Accelerating the understanding of cancer biology through the lens of genomics

Cancer Genome Landscapes

Genomic Sequencing for Cancer Diagnosis and Therapy.

Radiogenomics: bridging the gap between imaging and genomics for precision oncology

Pathogenomics for accurate diagnosis, treatment, prognosis of oncology: a cutting edge overview

Tumor immunology in the age of single-cell genomics

Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks

Deciphering oncogenic drivers: from single genes to integrated pathways.

The Cancer Genomics and Global Cancer Genome Collaboration

Pharmacogenetics Of Cancer Therapy: Breakthroughs From Beyond?

The Cancer Genome Anatomy Project: EST sequencing and the genetics of cancer progression

Genetic Expression in Cancer Research: Challenges and Complexity

Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity

Cancer systems biology: exploring cancer-associated genes on cellular networks

An expanded universe of cancer targets

A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology

The role of genomics in global cancer prevention

Radiogenomics: a key component of precision cancer medicine

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic

Integrative analysis of dysfunctional modules driven by genomic alterations at system level across 11 cancer types.

Understanding cervical cancer at single-cell resolution